Phase 3 data support “changing the current standard of care to now include neoadjuvant and adjuvant pembrolizumab,” according to Ravindra Uppaluri, MD, PhD.

Researchers sought to determine whether dual-targeted CAR-T therapy would be effective for patients with relapsed or refractory MCL.

Colorectal Cancer Screening Scale is a gender-specific instrument developed and validated to assess for barriers to colorectal cancer screening among men.

Addition of neoadjuvant and adjuvant pembrolizumab to standard care significantly improves event-free survival.